Dyrk1a-KO 基因敲除小鼠

1. Arbones, Maria L, Thomazeau, Aurore, Nakano-Kobayashi, Akiko, Hagiwara, Masatoshi, Delabar, Jean M. 2018. DYRK1A and cognition: A lifelong relationship. In Pharmacology & therapeutics, 194, 199-221. doi:10.1016/j.pharmthera.2018.09.010. https://pubmed.ncbi.nlm.nih.gov/30268771/

2. de Souza, Márcia Maria, Cenci, Arthur Ribeiro, Teixeira, Kerolain Faoro, de Oliveira, Aldo Sena, Andricopulo, Adriano Defini. . DYRK1A Inhibitors and Perspectives for the Treatment of Alzheimer's Disease. In Current medicinal chemistry, 30, 669-688. doi:10.2174/0929867329666220620162018. https://pubmed.ncbi.nlm.nih.gov/35726411/

3. Lan, Cong, Chen, Caiyu, Qu, Shuang, Wu, Gengze, Zeng, Chunyu. 2022. Inhibition of DYRK1A, via histone modification, promotes cardiomyocyte cell cycle activation and cardiac repair after myocardial infarction. In EBioMedicine, 82, 104139. doi:10.1016/j.ebiom.2022.104139. https://pubmed.ncbi.nlm.nih.gov/35810562/

4. Yang, Yuping, Fan, Xiaoxiao, Liu, Yongjian, Zhang, Yuanyuan, Liu, Yonggang. 2023. Function and inhibition of DYRK1A: Emerging roles of treating multiple human diseases. In Biochemical pharmacology, 212, 115521. doi:10.1016/j.bcp.2023.115521. https://pubmed.ncbi.nlm.nih.gov/36990324/

5. Deshmukh, V, O'Green, A L, Bossard, C, Hood, J, Yazici, Y. 2019. Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment. In Osteoarthritis and cartilage, 27, 1347-1360. doi:10.1016/j.joca.2019.05.006. https://pubmed.ncbi.nlm.nih.gov/31132406/